Omega-3 Fatty Acids and Brain Health: DHA, EPA, and Beyond

Omega-3 fatty acids are a family of polyunsaturated fats whose long-chain forms — eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) — are essential structural and functional building blocks for the brain. Of the three omega-3s most often discussed, alpha-linolenic acid (ALA) is the plant-derived precursor, while EPA and DHA are the marine-derived active forms your brain actually uses. The clinical evidence for omega-3 and cognition is real, more nuanced than supplement marketing suggests, and meaningfully dependent on who is taking it and at what dose. This guide walks through the biology, the evidence as it actually stands in 2026, and the practical questions worth answering before you take a daily capsule.

What are omega-3 fatty acids and where do they come from?

Omega-3 fatty acids are a family of polyunsaturated fats defined by the position of their first double bond — three carbons in from the methyl end of the molecule. Three forms matter for human health: alpha-linolenic acid (ALA), the 18-carbon plant-derived precursor found in flaxseed, chia, walnuts, and rapeseed oil; eicosapentaenoic acid (EPA), the 20-carbon marine form; and docosahexaenoic acid (DHA), the 22-carbon marine form. The body cannot manufacture ALA from scratch, which is why it's classed as essential, and the long-chain forms (EPA and DHA) are technically conditionally essential because adults convert ALA to them only weakly.⁸

In dietary terms, ALA comes from a small group of seeds and oils; EPA and DHA come from oily fish (salmon, mackerel, sardines, herring, anchovies), some shellfish, and increasingly from algal oils for vegan and vegetarian supplementation. The NHS recommends two portions of fish per week, one of which should be oily — guidance that translates to roughly 450–500 mg of EPA+DHA per day on average across the week, which sits near the European Food Safety Authority's 250 mg/day baseline recommendation for general adult cardiovascular and neural health.

Worth flagging up front: dietary intake is one thing, brain availability is another. The brain selectively incorporates DHA into its phospholipid membranes from circulating blood lipids — meaning what shows up in your red blood cells is a better proxy for brain status than what's on your plate. This is the foundation of the Omega-3 Index, which we'll come back to.

Why do DHA and EPA matter so much for the brain?

Of all the fatty acids in the brain, DHA is the standout. It accounts for approximately 30–40% of the polyunsaturated fatty acids in the grey matter of the cerebral cortex, embedded in the phospholipid bilayers of neuronal cell membranes.¹ This isn't a passive packaging role. The high DHA content of neuronal membranes determines their fluidity, which in turn shapes how proteins like ion channels, receptors, and transporters move within the membrane and how efficiently neurons communicate at synapses. DHA also supports neurogenesis — the formation of new neurons — and the growth of neurites, the projections through which neurons connect to one another.¹

EPA's role is different. EPA is present in the brain in much smaller quantities than DHA, and it appears to act less as a structural component and more as a signalling lipid. EPA is the precursor to a family of anti-inflammatory eicosanoids and to specialised pro-resolving mediators called resolvins and protectins, which dampen the kind of chronic, low-grade neuroinflammation increasingly linked to mood disorders and cognitive decline. EPA also has well-characterised effects on blood vessel function and platelet aggregation, which matter for the brain's vascular health.^1,2

Here's where it gets interesting: this functional division — DHA as the structural fat, EPA as the signalling fat — turns out to predict which omega-3 formulations work for which conditions. Trials of EPA-predominant supplements (those with at least 60% EPA) show consistent benefit for depressive symptoms; DHA-predominant trials don't. Conversely, trials in age-related cognitive decline and mild cognitive impairment lean more positive when DHA dosing is generous. The implication is that "omega-3" is too coarse a label — the EPA-to-DHA ratio is doing real biological work, and if you grab a generic fish-oil capsule without checking the ratio, you're leaving outcomes to chance.

How do DHA and EPA differ for cognitive function and mood?

The cleanest way to see the DHA-versus-EPA distinction is alongside the evidence base, because that's where the clinical implications become concrete.

What does this mean in practice? If you're choosing a supplement primarily for mood support, the EPA-to-DHA ratio matters more than the total dose — formulations with ≥60% EPA have the cleanest meta-analytic support.^3,10 If you're choosing one for cognitive support in the context of age-related decline, DHA-leaning formulations or balanced fish oils dosed in the 1,000–2,000 mg/day range have stronger support.^4,9 For general maintenance in a healthy, well-nourished adult under 70, the case for any supplementation at all is weaker — we'll get to why.

What does the clinical evidence actually show?

This is the section where most consumer omega-3 guides oversimplify, and the picture deserves a clearer reading.

The strongest contemporary evidence is the 2025 systematic review and dose-response meta-analysis published in Scientific Reports. The authors pooled 58 randomised controlled trials of omega-3 supplementation on cognitive function. The headline finding: dose-response benefits became statistically significant at approximately 2,000 mg/day of combined EPA+DHA, with the strongest effects in attention, perceptual speed, language, and primary memory.⁴ The GRADE quality of evidence was rated low for attention and moderate for perceptual speed — meaning the signal is real, but the trials underlying it vary in design quality.

Several earlier landmark trials anchor the more specific population findings. The MIDAS trial (Yurko-Mauro 2010) randomised 485 adults aged 55+ with age-related cognitive decline to either 900 mg/day algal DHA or placebo for 24 weeks. The DHA group showed a statistically significant improvement on the Paired Associate Learning test — a measure of episodic memory — equivalent to a learning-and-memory profile about three years younger.⁹ The trial was industry-funded by Martek Biosciences, which is worth noting but does not automatically discount the result.

In a different population — adults already diagnosed with mild-to-moderate Alzheimer's disease — the evidence is markedly less encouraging. The OmegAD trial (Freund-Levi 2006) randomised 174 such patients to 1.7 g DHA plus 0.6 g EPA daily or placebo for six months and found no overall difference in cognitive decline measured by MMSE or ADAS-cog, though a small subgroup with very mild impairment (MMSE >27) showed a slowed decline.¹¹ A larger 2010 JAMA trial (Quinn et al.) randomised 402 mild-to-moderate Alzheimer's patients to 2 g/day algal DHA or placebo for 18 months and likewise found no slowing of cognitive or functional decline.¹²

The point is consistent: omega-3 supplementation appears to help in earlier-stage cognitive vulnerability and to disappoint in established neurodegeneration. The biology aligns — once neuronal loss has progressed, more structural fat can't rebuild what's already gone. The practical takeaway is that timing matters as much as formulation if you're thinking about long-term brain health for yourself or someone in your family.

A 2025 overview of systematic reviews in Nutrients (Barros et al.) reinforces this pattern at the higher level: across non-dementia and mild-cognitive-impairment populations, omega-3 supplementation showed cognitive benefits.¹³ Taken alongside OmegAD and the JAMA DHA trial above, the broader literature points to a clear divide between early-stage cognitive vulnerability (where omega-3 helps) and established neurodegeneration (where it does not).

Then there's the cognitively healthy population. The UK PUFA Trial (Dangour 2010) randomised 867 community-dwelling adults aged 70–79 — with no cognitive complaints — to roughly 700 mg/day combined EPA+DHA or placebo for two years. The result: no significant difference in any cognitive outcome.⁵ A different German trial (Witte 2014) in 65 healthy 50–75-year-olds found that 26 weeks of 2.2 g/day combined EPA+DHA did improve executive function and white-matter microstructure — and the improvement tracked with how much each participant's Omega-3 Index actually rose.⁶ Read alongside MIDAS, the message becomes coherent: if you're a healthy older adult at adequate baseline status, modest doses don't reliably move the needle, but generous doses sustained over six months can.

Why do omega-3 trials sometimes disagree with each other?

The honest answer is that many trials ignore baseline status — and you can't expect a supplement to help someone who already has enough of the nutrient.

This is the case Harris and von Schacky made when they proposed the Omega-3 Index in 2004. The Omega-3 Index is the EPA+DHA content of red blood cells, expressed as a percentage of total fatty acids. They set the optimal range at 8–11%, with values below 4% defined as high risk and 4–8% as moderate risk.⁷ This is a marine-fatty-acid biomarker that tracks long-term tissue status — not a snapshot of yesterday's lunch.

Why does this matter for trials? Because a participant entering a study at an Omega-3 Index of 9% has very little room to gain from supplementation. A participant entering at 3% has a lot of room. If your trial recruits participants without measuring baseline status — which most have — you're pooling people in both situations, and the average effect dilutes towards null. The 2025 dose-response meta-analysis quietly confirmed this pattern: effect sizes were larger when participants were stratified by blood EPA+DHA levels rather than treatment group alone.⁴

The practical implication for an individual reader is straightforward. If you eat oily fish twice a week and live in a region with reasonable seafood access, your baseline status is probably already moderate. If you eat almost no fish, your baseline is probably low and the case for supplementation — or for changing your diet — is stronger.

How does omega-3 interact with B vitamins for brain health?

This is one of the most interesting findings in the long-term brain health literature, and it doesn't appear in most consumer omega-3 content.

The VITACOG trial originally tested whether high-dose B vitamins (folic acid 0.8 mg, vitamin B6 20 mg, vitamin B12 0.5 mg daily) would slow brain atrophy in older adults with mild cognitive impairment. A 2015 follow-up analysis by Jernerén and colleagues asked a different question: did baseline omega-3 status modify the B-vitamin effect?

The answer was striking. In participants with high baseline plasma omega-3 fatty acids (above 590 μmol/L combined EPA+DHA), B-vitamin supplementation slowed the rate of whole-brain atrophy by 40% compared with placebo. In participants with low baseline omega-3, the B vitamins had no detectable effect on atrophy.¹⁴

In other words: the B vitamins only worked if your omega-3 tank was already full. The mechanism is biologically coherent — B vitamins lower homocysteine, an amino acid implicated in vascular and neuronal damage, but the downstream protective steps appear to require adequate long-chain omega-3 to express that benefit.

The wider implication for you is that nutrients for the brain don't work as independent levers. They work as a system. This is why isolated single-nutrient strategies — including omega-3 alone, or B vitamins alone — often underperform combined approaches that ensure baseline adequacy across the relevant pathways. If you've ever wondered why a single-supplement experiment didn't seem to move the needle, the answer is often that another piece of the system was the limiting factor.

Can you get enough omega-3 from a plant-based diet?

The honest answer is: from food alone, probably not — at least not at the long-chain forms (EPA and DHA) that matter for the brain.

The biochemistry is clear. ALA, the plant-form omega-3 from flaxseed, chia, walnuts, hempseed, and rapeseed oil, has to be converted by your body to EPA and then to DHA through a multi-step enzymatic process. In healthy adults, the conversion of ALA to DHA is consistently measured at less than 1%, with EPA conversion only modestly higher.⁸ Premenopausal women appear to convert somewhat more efficiently than men, which has been attributed to oestrogen's effects on the relevant enzymes, but even then the absolute amounts produced fall short of what supplementation trials typically deliver.

What does this mean in practice for vegans, vegetarians, and people who simply don't eat fish? The pragmatic route is algal oil. Algae are where fish get their DHA in the first place — fish concentrate it from their diet rather than synthesising it themselves. Algal DHA supplements deliver pre-formed DHA (and increasingly EPA-containing variants) without involving the marine food chain. The MIDAS trial used algal DHA at 900 mg/day with positive results.⁹ Algal oil sidesteps both the conversion bottleneck and the dietary fish constraint.

Ground flaxseed and other ALA-rich foods are still worth including in your diet. They contribute to background dietary adequacy, support cardiovascular health, and are useful if you want a varied omega-3 intake. But they aren't a brain-DHA strategy on their own.

How much DHA and EPA should you actually take?

There's no single right answer, and the variation in published guidance reflects honest uncertainty.

For general adult health, the European Food Safety Authority's adequate intake is 250 mg/day combined EPA+DHA, which you can reach through two portions of fish per week, one of them oily. The NHS endorses the same dietary approach. The World Health Organisation's broader recommendation falls in a similar range.

If you're specifically looking to support cognitive health in age-related decline or mild cognitive impairment, the 2025 dose-response meta-analysis suggests benefits become statistically significant around 2,000 mg/day combined EPA+DHA, sustained over months.⁴ For adjunctive mood support, EPA-predominant trials cover a wide dose range: Sublette's meta-analysis found benefit across 200–2,200 mg/day of EPA in excess of DHA,³ while a more recent meta-analysis specifically found efficacy at EPA doses ≤1,000 mg/day in ≥60% EPA formulations.¹⁰

A few practical notes worth highlighting:

• Doses above 3 g/day of combined EPA+DHA from supplements should not be taken without medical supervision, particularly if you take anticoagulant or antiplatelet medication. The European Food Safety Authority concluded that long-term intake up to 5 g/day is unlikely to cause adverse effects in the general population, but the higher the dose, the more relevant individual interactions become.
• Taking with food, particularly with a meal containing some fat, improves absorption substantially.
• Quality matters more than headline dose. Look for the EPA and DHA content per serving (not just "1,000 mg fish oil" — much of that may be other fatty acids), and prefer products with third-party purity testing for heavy metals and oxidation markers.
• Storage matters. Omega-3s are oxidatively fragile. Keep capsules cool, dark, and away from heat.

UK supplements aren't blanket-recommended by the NHS for the general adult population because the evidence in cognitively healthy adults is inconclusive. The framing that holds up is this: supplements make most sense for you when the dietary route is genuinely unavailable, when your baseline status is likely low, or when a specific clinical context (mild cognitive impairment, perinatal pregnancy needs, persistent low mood as part of a broader care plan) makes the targeted benefit case stronger.

Who has the strongest evidence to benefit from omega-3 supplementation?

Pulling the evidence together honestly:

• Adults with mild cognitive impairment or early age-related cognitive decline. Best evidence: the 2025 Shahinfar meta-analysis,⁴ the 2025 Barros overview of systematic reviews,¹³ and the MIDAS trial.⁹
• Adults with persistent low mood, particularly as adjunctive support alongside a broader care plan. Best evidence: the Sublette and Liao EPA meta-analyses, with EPA-predominant formulations (≥60% EPA), with the more recent meta-analysis finding efficacy specifically at EPA doses ≤1,000 mg/day.^3,10
• People whose dietary intake is genuinely low — vegans, vegetarians without algal supplementation, people who don't eat fish or shellfish, people in regions with limited seafood access. The case is straightforward dietary adequacy rather than therapeutic benefit.
• Pregnant and breastfeeding women. DHA crosses the placenta and supports foetal brain development; algal DHA supplementation is recommended for those who don't consume oily fish. (This is outside the cognitive-ageing scope of this article but worth mentioning for context.)

Conversely, the populations where the evidence is weakest:

• Cognitively healthy older adults at adequate baseline status. The UK PUFA Trial⁵ and similar studies have repeatedly failed to show cognitive benefit.
• People with established moderate-to-advanced dementia. OmegAD¹¹ and Quinn 2010¹² both came back null on primary outcomes.

If you sit in the "already healthy, eat fish twice a week" group, a supplement is unlikely to change much for you in cognitive terms — though there may be other reasons (cardiovascular, anti-inflammatory) to keep your intake adequate. If you sit in any of the first three groups, the case is more compelling, with the specifics of dose and EPA-to-DHA ratio mattering more as your reasons get more clinical.

This article is educational and does not constitute medical advice. If you are pregnant, breastfeeding, taking medication, or have a health condition, discuss any new supplement with your GP or pharmacist before starting.

Supporting Your Brain Health with BrainSmart

BrainSmart's range of brain health supplements is formulated to support cognitive function, memory, focus, and mood through evidence-based ingredients at clinically studied dosages.

Explore our range:

• BrainSmart Ultra — Comprehensive brain support
• BrainSmart Focus — Concentration and mental clarity
• BrainSmart Memory — Memory and recall
• BrainSmart Mood — Emotional wellbeing and stress

Tom Kaplan

Brain Health Writer at BrainSmart

Tom Kaplan is a specialist health writer focused on cognitive health, brain nutrition, and evidence-based approaches to supporting mental performance across the lifespan. His work draws on peer-reviewed research across neuroscience, nutritional psychiatry, and cognitive psychology — translating complex clinical findings into clear, practical guidance that helps readers make informed decisions about their brain health. Read Full Bio →